The company has established partnerships with a number of partners,  over and above its own organisation, in order to enable us to bring arfolitixorin to market.

Merck & Cie – experts in the processing of substance

Merck & CIE is a subsidiary of Merck KGaA, Germany, with which Isofol has a strategic research and development partnership. The partnership offers many synergies in which Isofol has specialised knowledge in the use of arfolitixorin for cancer treatment, and Merck has knowledge of synthesising a stable API (active pharmaceutical ingredient) of [6R]-MTHF and formulation of a stable and durable drug (arfolitixorin). Through a global licensing agreement with Merck KGaA, Germany, Isofol has the exclusive right to develop and commercialise arfolitixorin for oncology. The license agreement with Merck also gives Isofol access to the unique patent-protected manufacturing process of arfolitixorin.

Surgical Oncology Laboratory – the folate research experts

Surgical Oncology Laboratory, SOL, (formerly a surgeon-oncology laboratory) at the Östra Hospital in Gothenburg, conducts research in surgery and oncology. SOL has internationally recognised experience of research on folates, especially on folates and colorectal cancer, with excellence in molecular biology. Isofol’s founder, Professor Bengt Gustavsson, also founded SOL.

Recipharm – commercial manufacturer

Recipharm is the commercial manufacturer of arfolitixorin and, together with Isofol and Merck, has validated the commercial full-scale production method.

CRO – Contract Research Organisation

Contract Research Organisation; a company that helps with the practical implementation of clinical trials, something that is absolutely necessary for a company of Isofol’s size. For example, CROs can help with statistical calculations and analyses. They can provide databases for study data, work with preclinical studies, label and distribute study drugs and be the company’s extended arm where resources and geographical distance make it difficult to work directly towards the hospitals. Among other things, Isofol collaborates with both international and local CROs such as Envigo, TFS, IDDI, LINK Medical Research, Precision for Medicine, Quartz-Bio, PK-Expert, Novotech, CMIC Shiftzero KK, Banook Group, Vigipharm, and others.


Sahlgrenska University Hospital

Sahlgrenska University Hospital (SU) serves as an important clinical development platform forto Isofol Medical. SU, located in Gothenburg, hosts key clinical and medical competence as well as having modern sites for performing Isofol Medical’s clinical trials.

About Sahlgrenska University Hospital
SU provides emergency and basic care for the Gothenburg region. SU also provides highly specialized care for the 1.7 million inhabitants in Western Sweden. SU was founded in 1997 when three hospitals merged; Mölndal Hospital, Sahlgrenska Hospital and Östra Hospital.

The research performed at the research institutions around SU, such as the Sahlgrenska Academy, has resulted in numerous achievements and innovations. Examples include development of the antibiotic PAS against tuberculosis and the blood thinning pharmaceutical Apekumarol. Both of these were developed after the Second World War as a result of research by Jörgen Lehmann. During the 70’s and 80’s, Arvid Carlsson and Björn Folkow successfully contributed to the development of the β-blocker Selokén and L-Dopa for Parkinson’s disease. Arvid Carlsson later won the Nobel Prize in Physiology or Medicine in 2000 for his work on the neurotransmitter Dopamine and his research lead to blockbuster pharmaceuticals. Furthermore, pharmaceuticals such as Losec and Nexium, from Astra Zeneca, have been made possible thanks to key contributions from Lars Olbe at the Sahlgrenska Academy.

Prof Bengt Gustavsson has been active at SU ever since he started his research on the effect of folates on cytotoxics in the late 1970s. The team around him at SU is closely knit, it includes medical scientists, nurses, and laboratory staff that have been involved in his clinical studies and research on the effects of folates on cytotoxics for decades.

Last updated 09-02-2021